An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
EClinicalMedicine (2020) - Comments
doi: 10.1016/j.eclinm.2020.100547  issn: 2589-5370  pubmed: 32984784 

Weihui Fu, Yan Liu, Li Liu, Huiliang Hu, Xiaobo Cheng, Ping Liu, Zhigang Song, Lijun Zha, Shimeng Bai, Tingting Xu, Songhua Yuan, Fengru Lu, Zhiying Shang, Yihong Zhao, Jing Wang, Jun Zhao, Longfei Ding, Jun Chen, Lin Zhang, Tongyu Zhu